SCHEMBL4352080

SCHEMBL4352080

CC[S+]([O-])c1ncc(C(=O)c2cc(F)ccc2OC(C)C)c(N)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 5/20 0.40
CDK4 P11802 5/20 0.40
CCND1 P24385 5/20 0.40
CDK2 P24941 5/20 0.40
ABL1 P00519 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.33
IRAK4 Q9NWZ3 1/20 0.33
KCNQ3 O43525 1/20 0.32
KCNQ2 O43526 1/20 0.32
PIK3CA P42336 1/20 0.32
RAB9A P51151 2/20 0.32
HPGD P15428 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
P2RX3 P56373 2/20 0.32
MKNK1 Q9BUB5 1/20 0.32
MKNK2 Q9HBH9 1/20 0.32
NTRK1 P04629 1/20 0.31
CSNK1D P48730 1/20 0.31
XDH P47989 1/20 0.31
HRH4 Q9H3N8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4359313 0.89 CDK1 (0.41) CDK1CDK4CCND1CDK2PTGDR2
SCHEMBL4354997 0.89 CDK1 (0.49) CDK1CDK4CCND1CDK2LMNA
SCHEMBL4358951 0.83 CDK4 (0.35) CDK1CDK4CCND1CDK2RAB9A
SCHEMBL4346982 0.83 CDK4 (0.35) CDK1CDK4CCND1CDK2ABL1
SCHEMBL13621474 0.83 CDK1 (0.49) CDK1CDK4CCND1CDK2LMNA
SCHEMBL4350072 0.81 HCRTR1 (0.36) CDK1CDK4CCND1CDK2PIK3CA
SCHEMBL4355071 0.81 CDK1 (0.42) CDK1CDK4CCND1CDK2PTGDR2
SCHEMBL4363762 0.80 SMN1; SMN2 (0.44) CDK1CDK4CCND1CDK2RAB9A
SCHEMBL4352778 0.79 CHRNA7 (0.39) CDK4CCND1RAB9ASMN1; SMN2MAPT
SCHEMBL4352552 0.79 CDK1 (0.40) CDK1CDK4CCND1CDK2PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US claimed
US-20060229330-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID J 2006-10-12 US claimed
US-20040162303-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID JOSEPH (US) 2004-08-19 US claimed
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US disclosed
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US disclosed
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US disclosed
CN-101044121-A 4-aminopyrimidine-5-one HOFFMANN LA ROCHE (CH) 2007-09-26 CN disclosed
US-7157455-B2 4-Aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2007-01-02 US disclosed
US-20060229330-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID J 2006-10-12 US disclosed
EP-1628619-A2 4-AMINOPYRIMIDINE-5-ONE F.HOFFMANN-LA ROCHE AG (CH) 2006-03-01 EP disclosed
US-20040162303-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID JOSEPH (US) 2004-08-19 US disclosed
WO-2004069139-A2 4-AMINOPYRIMIDIN-5-YL-METHANONE DERIVATIVES FOR INHIBITION OF CDK4 ACTIVITY F.HOFFMANN-LA ROCHE AG (CH) 2004-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162303-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK6 CDK1 6/4885CDK4 1/4885CCND1 32/4885
US-20060229330-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK2 CDK1 6/4885CDK4 1/4885CCND1 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.